JOUNCE THERAPEUTICS, INC.

(JNCE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/19/2022 05/20/2022 05/23/2022 05/24/2022 05/25/2022 Date
4.52(c) 4.69(c) 4.65(c) 4.35(c) 3.89(c) Last
364 417 162 296 356 590 444 840 894 840 Volume
-1.74% +3.76% -0.85% -6.45% -10.57% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 14,4 M - -
Net income 2022 -130 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,59x
Yield 2022 -
Sales 2023 18,6 M - -
Net income 2023 -141 M - -
Net Debt 2023 - - -
P/E ratio 2023 -1,67x
Yield 2023 -
Capitalization 201 M 201 M -
Capi. / Sales 2022 13,9x
Capi. / Sales 2023 10,8x
Nbr of Employees 137
Free-Float 79,9%
More Financials
Company
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. The Company has developed a suite of integrated technologies that consist of its Translational Science Platform, enabling it to... 
Sector
Biotechnology & Medical Research
Calendar
06/02 | 01:30pmPresentation
More about the company
Ratings of Jounce Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about JOUNCE THERAPEUTICS, INC.
05/23Piper Sandler Lowers Jounce Therapeutics' Price Target to $9 From $17, Maintains Overwe..
MT
05/17Jounce Therapeutics to Present at Upcoming Investor Conferences
AQ
05/12NORTH AMERICAN MORNING BRIEFING : Stocks Seen -3-
DJ
05/11Jounce Therapeutics' Shares Drop After Baird Downgrade
MT
05/11Baird Downgrades Jounce Therapeutics to Neutral From Outperform, Adjusts Price Target t..
MT
05/06Raymond James Upgrades Jounce Therapeutics to Strong Buy From Outperform, Adjusts Price..
MT
05/05JOUNCE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/05TRANSCRIPT : Jounce Therapeutics, Inc., Q1 2022 Earnings Call, May 05, 2022
CI
05/05Jounce Therapeutics Reports First Quarter 2022 Financial Results
AQ
05/05Jounce Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
04/28Jounce Therapeutics to Announce First Quarter 2022 Financial Results and Host Conferenc..
AQ
04/21JOUNCE THERAPEUTICS TO PARTICIPATE I : Deep Dive into 'Myeloid Checkpoint' Therapeutics in..
AQ
04/20JOUNCE THERAPEUTICS TO PARTICIPATE I : Deep Dive into “Myeloid Checkpoint” The..
AQ
03/16SMBC Nikko Starts Jounce Therapeutics at Outperform With $17 Price Target
MT
03/11JOUNCE THERAPEUTICS : Corporate Presentation
PU
More news
News in other languages on JOUNCE THERAPEUTICS, INC.
05/11Les actions de Jounce Therapeutics chutent après la rétrogradation de Baird
05/05Jounce Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 ma..
03/02Jounce Therapeutics, Inc. annonce ses résultats pour le quatrième trimestre clos le 31 ..
03/02Jounce Therapeutics, Inc. annonce ses résultats pour l'année complète se terminant le 3..
2021Jounce Therapeutics réduit sa perte nette par action au troisième trimestre
More news
Analyst Recommendations on JOUNCE THERAPEUTICS, INC.
More recommendations
Chart JOUNCE THERAPEUTICS, INC.
Duration : Period :
Jounce Therapeutics, Inc. Technical Analysis Chart | JNCE | US4811161011 | MarketScreener
Technical analysis trends JOUNCE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 3,89 $
Average target price 14,00 $
Spread / Average Target 260%
EPS Revisions
Managers and Directors
Richard Murray President, Chief Executive Officer & Director
Kimberlee Cobleigh Drapkin Chief Financial Officer & Treasurer
Perry A. Karsen Chairman
Elizabeth G. Trehu Chief Medical Officer
Stephen Farrand Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
JOUNCE THERAPEUTICS, INC.-53.41%201
GILEAD SCIENCES, INC.-10.47%81 543
REGENERON PHARMACEUTICALS, INC.9.40%74 440
VERTEX PHARMACEUTICALS23.33%69 269
WUXI APPTEC CO., LTD.-22.98%39 423
BIONTECH SE-40.00%37 588